\Program Files\Common Files\System\Mapi\1033\NT





ain nodes :
8 9 10 11 12 14
ng nodes :
1 2 3 4 5 6
ain bonds :
2-8 8-12 8-9 9-10 9-11
ng bonds :
1-2 1-6 2-3 3-4 4-5 5-6
act/norm bonds :
2-8 8-12 8-9 9-10 9-11
rmalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
olated ring systems :
containing 1 :

:N,CH

tch level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:Atom 14:Atom 15:CLASS
neric attributes :
12:
Saturation : Unsaturated
14:
Saturation : Unsaturated

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10658111.str



chain nodes :
8 9 10 11 12 66 67
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 20 21 22 23 24 25 32 33 34 35
36 37 38 39 40 41 42 43 48 49 50 51 52 53 56 57 58 59 60 61
chain bonds :
8-12 8-9 8-66 9-10 9-11 66-67
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 20-21
20-25 21-22 22-23 23-24 24-25 32-33 32-37 33-34 34-35 35-36 36-37 38-39
38-43 39-40 40-41 41-42 42-43 48-49 48-53 49-50 50-51 51-52 52-53 56-57
56-61 57-58 58-59 59-60 60-61
exact/norm bonds :
8-12 8-9 8-66 9-10 9-11 66-67
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 20-21
20-25 21-22 22-23 23-24 24-25 32-33 32-37 33-34 34-35 35-36 36-37 38-39
38-43 39-40 40-41 41-42 42-43 48-49 48-53 49-50 50-51 51-52 52-53 56-57
56-61 57-58 58-59 59-60 60-61

```
isolated ring systems :
containing 1 : 14 : 20 :


G1:N,CH

G2:[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom
21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  32:Atom  33:Atom  34:Atom  35:Atom
36:Atom  37:Atom  38:Atom  39:Atom  40:Atom  41:Atom  42:Atom  43:Atom  48:Atom
49:Atom  50:Atom  51:Atom  52:Atom  53:Atom  56:Atom  57:Atom  58:Atom  59:Atom
60:Atom  61:Atom  66:CLASS  67:Atom
Generic attributes :
12:
Saturation              : Unsaturated
67:
Saturation              : Unsaturated



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:01:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  29480 TO ITERATE

  3.4% PROCESSED    1000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       579343 TO   599857
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840
```

L3 SCREEN CREATED

=> screen 2026 OR 2039 OR 2040 OR 2045 OR 2047

L4 SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10658111 (filter).str



chain nodes :
8 9 10 11 12 66 67
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 20 21 22 23 24 25 32 33 34 35
36 37 38 39 40 41 42 43 48 49 50 51 52 53 56 57 58 59 60 61
chain bonds :
8-12 8-9 8-66 9-10 9-11 66-67
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 20-21
20-25 21-22 22-23 23-24 24-25 32-33 32-37 33-34 34-35 35-36 36-37 38-39
38-43 39-40 40-41 41-42 42-43 48-49 48-53 49-50 50-51 51-52 52-53 56-57
56-61 57-58 58-59 59-60 60-61

```
exact/norm bonds :
8-12  8-9  8-66  9-10  9-11  66-67
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25  32-33  32-37  33-34  34-35  35-36  36-37  38-39
38-43  39-40  40-41  41-42  42-43  48-49  48-53  49-50  50-51  51-52  52-53  56-57
56-61  57-58  58-59  59-60  60-61
isolated ring systems :
containing 1 : 14 : 20 :


G1:N,CH

G2:[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom
21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  32:Atom  33:Atom  34:Atom  35:Atom
36:Atom  37:Atom  38:Atom  39:Atom  40:Atom  41:Atom  42:Atom  43:Atom  48:Atom
49:Atom  50:Atom  51:Atom  52:Atom  53:Atom  56:Atom  57:Atom  58:Atom  59:Atom
60:Atom  61:Atom  66:CLASS  67:Atom
Generic attributes :
12:
Saturation              : Unsaturated
67:
Saturation              : Unsaturated




L5      STRUCTURE UPLOADED

=> que L5 AND L3 NOT L4

L6   QUE L5 AND L3 NOT L4

=> d l6
L6 HAS NO ANSWERS
L3              SCR 1840
L4              SCR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L6              QUE  L5 AND L3 NOT L4


=> s l6 sss sam
SAMPLE SEARCH INITIATED 18:02:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  22218 TO ITERATE

  4.5% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       435446 TO   453274
PROJECTED ANSWERS:             162 TO      726

L7            1 SEA SSS SAM L5 AND L3 NOT L4

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840

L8    SCREEN CREATED

=> screen 2026 OR  2039 OR  2040 OR  2045 OR  2047

L9    SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10658111 (a).str
```





















chain nodes :
8 9 10 11 12 35 42
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 20 21 22 23 24 25 28 29 30 31 32 33
chain bonds :
8-12 8-9 8-42 9-10 9-11 35-42

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25  28-29  28-33  29-30  30-31  31-32  32-33
exact/norm bonds :
8-12  8-9  8-42  9-10  9-11  35-42
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25  28-29  28-33  29-30  30-31  31-32  32-33
isolated ring systems :
containing 1 : 14 : 20 :


G1:N,CH

G2:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom
21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  29:Atom  30:Atom  31:Atom
32:Atom  33:Atom  35:Atom  42:CLASS
Generic attributes :
12:
Saturation              : Unsaturated
35:
Saturation              : Unsaturated




L10     STRUCTURE UPLOADED

=> que L10 AND L8 NOT L9

L11  QUE L10 AND L8 NOT L9

=> d l11
L11 HAS NO ANSWERS
L8              SCR 1840
L9              SCR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L11             QUE  L10 AND L8 NOT L9


=> s l11 sss sam
SAMPLE SEARCH INITIATED 18:06:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  22218 TO ITERATE

  4.5% PROCESSED    1000 ITERATIONS                                  1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
```

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       435446 TO   453274
PROJECTED ANSWERS:             162 TO      726

L12           1 SEA SSS SAM L10 AND L8 NOT L9

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840

L13   SCREEN CREATED

=> screen 2026 OR  2039 OR  2040 OR  2045 OR  2047

L14   SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10658111 (c).str
```





















chain nodes :
8 9 10 11 12 35 42
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 20 21 22 23 24 25 28 29 30 31 32 33
chain bonds :
8-12 8-9 8-42 9-10 9-11 35-42

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25  28-29  28-33  29-30  30-31  31-32  32-33
exact/norm bonds :
8-12  8-9  8-42  9-10  9-11  35-42
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25  28-29  28-33  29-30  30-31  31-32  32-33
isolated ring systems :
containing 1 : 14 : 20 : 28 :


G1:N,CH

G2:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom
21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  29:Atom  30:Atom  31:Atom
32:Atom  33:Atom  35:Atom  42:CLASS
Generic attributes :
12:
Saturation              : Unsaturated
35:
Saturation              : Unsaturated




L15     STRUCTURE UPLOADED

=> que L15 AND L13 NOT L14

L16  QUE L15 AND L13 NOT L14

=> d l16
L16 HAS NO ANSWERS
L13             SCR 1840
L14             SCR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L15             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L16             QUE  L15 AND L13 NOT L14


=> s l16 sss sam
SAMPLE SEARCH INITIATED 18:09:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  22218 TO ITERATE

  4.5% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
```

BATCH **COMPLETE**
PROJECTED ITERATIONS: 435446 TO 453274
PROJECTED ANSWERS: 162 TO 726

L17 1 SEA SSS SAM L15 AND L13 NOT L14

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L18 SCREEN CREATED

=> screen 2026 OR 2039 OR 2040 OR 2045 OR 2047

L19 SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10658111 (d).str



chain nodes :
8 9 10 11 12 14
ring nodes :
1 2 3 4 5 6
chain bonds :
2-8 6-14 8-12 8-9 9-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-8 6-14 8-12 8-9 9-10 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 14:Atom
Generic attributes :
12:
Saturation : Unsaturated
14:

Saturation : Unsaturated

L20 STRUCTURE UPLOADED

=> que L20 AND L18 NOT L19

L21 QUE L20 AND L18 NOT L19

=> d l21
L21 HAS NO ANSWERS
L18 SCR 1840
L19 SCR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L20 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.
L21 QUE L20 AND L18 NOT L19

=> s l21 sss sam
SAMPLE SEARCH INITIATED 18:11:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 536 TO ITERATE

100.0% PROCESSED 536 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9331 TO 12109
PROJECTED ANSWERS: 11 TO 389

L22 10 SEA SSS SAM L20 AND L18 NOT L19

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L23 SCREEN CREATED

=> screen 2026 OR 2039 OR 2040 OR 2045 OR 2047

L24 SCREEN CREATED

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10658111 (e).str





chain nodes :
8 9 10 11 12 14
ring nodes :
1 2 3 4 5 6
chain bonds :
2-8 8-12 8-9 9-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-8 8-12 8-9 9-10 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 14:Atom 15:CLASS
Generic attributes :
12:
Saturation : Unsaturated
14:
Saturation : Unsaturated

L25 STRUCTURE UPLOADED

=> que L25 AND L23 NOT L24

L26 QUE L25 AND L23 NOT L24

=> d 126

L26 HAS NO ANSWERS
L23 SCR 1840
L24 SCR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L25 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.
L26 QUE L25 AND L23 NOT L24

=> s l26 sss sam
SAMPLE SEARCH INITIATED 18:13:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 536 TO ITERATE

100.0% PROCESSED 536 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9331 TO 12109
PROJECTED ANSWERS: 11 TO 389

L27 10 SEA SSS SAM L25 AND L23 NOT L24

=> s l26 sss ful
FULL SEARCH INITIATED 18:14:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11233 TO ITERATE

100.0% PROCESSED 11233 ITERATIONS 162 ANSWERS
SEARCH TIME: 00.00.01

L28 162 SEA SSS FUL L25 AND L23 NOT L24

=> => s l28
L29 6 L28

=> d l29 1-6 bib,ab,hitstr

L29 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:182368 CAPLUS
DN 140:229401
TI Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
IN Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
PA USA
SO U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004043388	A1	20040304	US 2002-234985	20020903
	US 2003165873	A1	20030904	US 2002-91177	20020304
PRAI	US 2001-272932P	P	20010302		
	US 2001-278233P	P	20010323		
	US 2001-329437P	P	20011015		
	US 2002-91177	A2	20020304		

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene gycol moiety to dexamethasone, is described.
IT **209412-01-1D**, conjugates **666838-13-7D**, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
RN 209412-01-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 666838-13-7 CAPLUS
CN Urea, N-[5-[[(aminocarbonyl)oxy]methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)


F
F
O
H2N—C—O—CH2
O
C—NH2
N
N
Cl
Cl

L29 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:142676 CAPLUS
DN 136:200105
TI Preparation of ueidopyridines as inhibitors of p38 and/or ZAP70 kinases.
IN Cochran, John; Galullo, Vincent; Bemis, Guy
PA USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014281	A1	20020221	WO 2001-US25015	20010810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001083237	A5	20020225	AU 2001-83237	20010810
	EP 1309560	A1	20030514	EP 2001-962021	20010810
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004506042	T2	20040226	JP 2002-519424	20010810
	US 2004044002	A1	20040304	US 2003-365719	20030211
PRAI	US 2000-224719P	P	20000811		
	WO 2001-US25015	W	20010810		

OS MARPAT 136:200105
AB Title compds. [I-IV; Q1, Q2 = ((substituted)) Ph, 5-6 membered aromatic heterocyclic ring system, 8-10 membered bicyclic ring system comprising aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring; R = H, R2, N(R2)2, OR2, SR2, CON(R2)2, SO2N(R2)2, CO2R2, COR2; RRY = 4-8 membered carbocyclyl, heterocyclyl; R2 = H, (substituted) alkyl, alkenyl; R7 = H, halo, alkyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, C(OH), CF; U = R, J; J = (substituted) alkyl; V = C(O)N:C(R)(NR2); RRN = atoms to form a 4-8 membered carbocyclyl, heterocyclyl; K = (substituted) alkyl], were prepared Thus, title compound (V) (multistep preparation given) inhibited p38 kinase with
IC50 = 0.031 μM.
IT **362058-05-7P 400728-24-7P 400728-25-8P**
400728-29-2P 400728-30-5P 400728-32-7P
400728-33-8P 400728-34-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ueidopyridines as inhibitors of p38 and/or ZAP70 kinases)
RN 362058-05-7 CAPLUS
CN L-Valine, [2-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-pyridinyl]-6-chlorophenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400728-24-7 CAPLUS
CN Urea, N-[5-[[(aminocarbonyl)oxy]methyl]-6-(4-fluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 400728-25-8 CAPLUS
CN Carbamic acid, [(dimethylamino)methylene]-, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methyl ester (9CI) (CA INDEX NAME)



RN 400728-29-2 CAPLUS
CN L-Valine, 2-[[[[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methoxy]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400728-30-5 CAPLUS
CN Carbamic acid, [(dimethylamino)methylene]-, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluorophenyl)-3-pyridinyl]methyl ester (9CI) (CA INDEX NAME)



RN 400728-32-7 CAPLUS
CN Urea, N-[6-[3-chloro-2-[(phosphonooxy)methyl]phenyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 400728-33-8 CAPLUS
CN L-Valine, [2-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-4-[[(aminocarbonyl)oxy]methyl]-2-pyridinyl]-6-chlorophenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400728-34-9 CAPLUS
CN Urea, N-[4-[[(aminocarbonyl)oxy]methyl]-6-[3-chloro-2-[(phosphonooxy)methyl]phenyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



IT **250122-81-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ueidopyridines as inhibitors of p38 and/or ZAP70 kinases)
RN 250122-81-7 CAPLUS
CN Urea, N-[5-[[(aminocarbonyl)oxy]methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



IT **250123-28-5P 400728-23-6P 400728-27-0P 400728-28-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ueidopyridines as inhibitors of p38 and/or ZAP70 kinases)
RN 250123-28-5 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 400728-23-6 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-5-formyl-2-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 400728-27-0 CAPLUS
CN Carbamic acid, (2-hydroxyethyl)-, [6-[(aminocarbonyl)(2,6-
difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methyl ester
(9CI) (CA INDEX NAME)



RN 400728-28-1 CAPLUS
CN 5,10-Dioxa-2,8-diazadodecanoic acid, 11,11-dimethyl-7-(1-methylethyl)-6,9-dioxo-, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methyl ester, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:713315 CAPLUS
DN 135:257249
TI Preparation of pyridines and pyrimidopyridazines as inhibitors of p38
IN Salituro, Francesco; Bemis, Guy; Evindar, Ghotas
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070695	A1	20010927	WO 2001-US9256	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2003528084	T2	20030924	JP 2001-568907	20010322
PRAI	US 2000-191358P	P	20000322		
	WO 2001-US9256	W	20010322		

OS MARPAT 135:257249
AB Title compds. [I, II, or III; wherein Het = substituted 5-7 membered heterocycle; n = 1-3; Q1 and Q2 = independently (un)substituted (hetero)aromatic ring; W = H, NR2SO2N(R2)2, NR2SO2NR2R3, NR2COOR2, NR2CON(R2)2, NR2COR2R3, NR2COR2, N(R2)2, COR2, CHOHR2, CON(R2)2, CO2R2, or (un)substituted alkyl or (hetero)cyclic ring; X = O or NR'; Z = CH or N; R' = H, alkyl, alkenyl, alkynyl, or (un)substituted Ph or heterocyclyl; R1 = H, alkyl(oxy), or OH; R2 = H or (un)substituted alkyl or alkenyl; R3 = (hetero)aromatic ring; or pharmaceutically acceptable salts thereof] were prepared as inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death, and response to extracellular stimuli. For example, coupling of 4-amino-2,6-dichlorobenzeneacetonitrile (preparation given) with 3,6-dichloropyridazine (60%), followed by addition of 2,4-difluorothiophenol (90%), reductive addition of 5-methyl-4-imidazolecarboxaldehyde, reduction of the nitrile to the carboxamide using H2SO4, and cyclization (90%), gave the pyrimidopyridazine I (Het = 5-methyl-4-imidazolyl, n = 1, X = NH, R1 = H) (IV). I, II, and III are useful for the treatment of p38-mediated conditions, such as inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious disease, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation, and conditions associated with prostaglandin endoperoxidase synthase 2 (no data).
IT **362058-04-6P 362058-05-7P 362058-06-8P**
362058-07-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridines and pyrimidopyridazines as inhibitors of p38)
RN 362058-04-6 CAPLUS
CN Glycine, [2-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-pyridinyl]-6-

chlorophenyl]methyl ester (9CI) (CA INDEX NAME)



RN 362058-05-7 CAPLUS
CN L-Valine, [2-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-pyridinyl]-6-chlorophenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362058-06-8 CAPLUS
CN Benzenemethanol, 2-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-pyridinyl]-6-chloro-, carbamate (ester) (9CI) (CA INDEX NAME)



RN 362058-07-9 CAPLUS
CN Acetamide, 2-[[[6-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-pyridinyl]-2-chlorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:802392 CAPLUS
DN 133:350242
TI Preparation of pyrido[1,2-c]pyrimidin-3-ones or 1,2-dihydro-pyrido[1,2-c]pyrimidin-3-ones as inhibitors of p38
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Harrington, Edmund Martin
PA Vertex Pharmaceuticals Incorporated, USA
SO U.S., 28 pp., Cont.-in-part of U.S. 5,945,418.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6147080	A	20001114	US 1997-862925	19970610
	US 5945418	A	19990831	US 1997-822373	19970320
	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	AU 738000	B2	20010906		
	EP 951467	A1	19991027	EP 1997-952517	19971217
	EP 951467	B1	20030402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	BR 9714415	A	20000418	BR 1997-14415	19971217
	TR 9902194	T2	20000621	TR 1999-9902194	19971217
	NZ 336146	A	20000929	NZ 1997-336146	19971217
	JP 2001506266	T2	20010515	JP 1998-527975	19971217
	AT 236165	E	20030415	AT 1997-952517	19971217
	PT 951467	T	20030829	PT 1997-952517	19971217
	EE 4191	B1	20031215	EE 1999-252	19971217
	ES 2202658	T3	20040401	ES 1997-952517	19971217
	TW 521071	B	20030221	TW 1997-86119152	19971218
	NO 9902960	A	19990817	NO 1999-2960	19990617
	HK 1023340	A1	20031224	HK 2000-102323	20000418
PRAI	US 1996-34288P	P	19961218		
	US 1997-822373	A2	19970320		
	US 1997-862925	A2	19970610		
	WO 1997-US23392	W	19971217		

OS MARPAT 133:350242
AB The title compds. [I or II; Q1, Q2 = (un)substituted Ph, 5-6 membered aromatic heterocyclic ring systems having one N atom; X = S, O, SO2, etc.; Y = C; R = H, alkyl; A = N, CH, C(alkyl), C(alkenyl), C(alkynyl); n = 1; R1 = H, alkyl, OH. O(alkyl)], useful as inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli, were prepared E.g., a multi-step synthesis of the compound I [Q1, Q2 = Ph; X = S; Y = C; R = H; A = N; n = 1; R1 = H] which showed IC50 of > 20 μM against p38 binding, was given.
IT **209412-01-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrido[1,2-c]pyrimidin-3-ones or 1,2-dihydro-pyrido[1,2-c]pyrimidin-3-ones as inhibitors of p38)

RN 209412-01-1 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:736658 CAPLUS
DN 131:336949
TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.
IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English

No J on Q2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958502	A1	19991118	WO 1999-US10291	19990511
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331460	AA	19991118	CA 1999-2331460	19990511
	AU 9937923	A1	19991129	AU 1999-37923	19990511
	AU 764047	B2	20030807		
	EP 1077943	A1	20010228	EP 1999-920427	19990511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	TR 200003300	T2	20010321	TR 2000-20000330	19990511
	BR 9911786	A	20010403	BR 1999-11786	19990511
	EE 200000610	A	20020415	EE 2000-610	19990511
	NZ 508653	A	20030725	NZ 1999-508653	19990511
	NO 2000005673	A	20010110	NO 2000-5673	20001110
	ZA 2000006987	A	20011126	ZA 2000-6987	20001128
	BG 105031	A	20011031	BG 2000-105031	20001207
	US 2002019393	A1	20020214	US 2000-746722	20001221
	US 6632945	B2	20031014		
PRAI	US 1998-85053P	P	19980511		
	US 1999-127626P	P	19990401		
	US 1999-129099P	P	19990413		
	WO 1999-US10291	W	19990511		

OS MARPAT 131:336949
AB Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicyclyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U = R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.; R2 = H, (substituted) alkyl, alkenyl], were prepared Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (preparation given), Tl2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed by aqueous acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compound (II). Tested title compds. inhibited recombinant p38 kinase with IC50 = 0.02-0.56 μM.
IT **250122-79-3P 250122-80-6P 250122-81-7P**

250122-82-8P 250122-91-9P 250122-92-0P
250122-93-1P 250122-94-2P 250122-95-3P
250122-96-4P 250122-97-5P 250122-98-6P
250122-99-7P 250123-00-3P 250123-01-4P
250123-02-5P 250123-03-6P 250123-04-7P
250123-05-8P 250123-06-9P 250123-07-0P
250123-08-1P 250123-09-2P 250123-10-5P
250123-11-6P 250123-12-7P 250123-13-8P
250123-14-9P 250123-15-0P 250123-16-1P
250123-17-2P 250123-18-3P 250123-19-4P
250123-20-7P 250123-21-8P 250123-22-9P
250123-23-0P 250123-24-1P 250123-25-2P
250123-26-3P 250123-27-4P 250123-28-5P
250123-30-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinylarylureas and related compds. as inhibitors of p38 kinase)

RN 250122-79-3 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[5-(hydroxymethyl)-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-80-6 CAPLUS
CN Urea, N-[5-[(acetyloxy)methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-81-7 CAPLUS
CN Urea, N-[5-[[(aminocarbonyl)oxy]methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-82-8 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-α-(2,6-dichlorophenyl)-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 250122-91-9 CAPLUS
CN Urea, N-[5-[(aminocarbonyl)amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-92-0 CAPLUS
CN Carbamic acid, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 250122-93-1 CAPLUS
CN Urea, N'-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250122-94-2 CAPLUS
CN Urea, N-[5-[(aminosulfonyl)amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-95-3 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[[(dimethylamino)sulfonyl]amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-96-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 250122-97-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250122-98-6 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-99-7 CAPLUS
CN Urea, N-[5-(aminomethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-00-3 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[(dimethylamino)methyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-01-4 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(1-hydroxy-1-methylethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-02-5 CAPLUS
CN Urea, N-[5-(1-amino-1-methylethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-03-6 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[1-(dimethylamino)-1-methylethyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-04-7 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(2-hydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-05-8 CAPLUS
CN Urea, N-[5-(2-aminoethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-06-9 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[2-(dimethylamino)ethyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-07-0 CAPLUS
CN 3-Pyridinepropanamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 250123-08-1 CAPLUS
CN 3-Pyridinepropanoic acid, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 250123-09-2 CAPLUS
CN 3-Pyridinepropanamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250123-10-5 CAPLUS
CN 3-Pyridineethanesulfonamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 250123-11-6 CAPLUS
CN 3-Pyridineethanesulfonamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250123-12-7 CAPLUS
CN Carbamic acid, [2-(1-piperazinyl)ethyl]-, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methyl ester (9CI) (CA INDEX NAME)



RN 250123-13-8 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-(2-hydroxyethyl)-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-14-9 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(2,4-difluorophenyl)-5-(2-hydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-15-0 CAPLUS
CN Urea, N-[4-(3-aminopropyl)-6-(3-chloro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-16-1 CAPLUS
CN Urea, N-[4-(3-aminopropyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-17-2 CAPLUS
CN Urea, N-[4-(3-aminopropyl)-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-18-3 CAPLUS

CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-(1-piperazinylmethyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-19-4 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-20-7 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-21-8 CAPLUS

CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 250123-22-9 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-23-0 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-24-1 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-25-2 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-1,5-diazocin-1(2H)-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-26-3 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-5-methyl-1,5-diazocin-1(2H)-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-27-4 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-28-5 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-30-9 CAPLUS
CN Urea, N-[5-amino-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



IT **250122-90-8 250123-29-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridinylarylureas and related compds. as inhibitors of p38 kinase)
RN 250122-90-8 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(2,4-difluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-29-6 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-α-(2,6-dichlorophenyl)-4-[[(methylsulfonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



IT **250122-86-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridinylarylureas and related compds. as inhibitors of p38 kinase)
RN 250122-86-2 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[5-formyl-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:424256 CAPLUS
DN 129:81749
TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English

Claims require J sub on Rx None found

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945418	A	19990831	US 1997-822373	19970320
	US 6147080	A	20001114	US 1997-862925	19970610
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	AU 738000	B2	20010906		
	EP 951467	A1	19991027	EP 1997-952517	19971217
	EP 951467	B1	20030402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	BR 9714415	A	20000418	BR 1997-14415	19971217
	NZ 336146	A	20000929	NZ 1997-336146	19971217
	JP 2001506266	T2	20010515	JP 1998-527975	19971217
	AT 236165	E	20030415	AT 1997-952517	19971217
	EE 4191	B1	20031215	EE 1999-252	19971217
	US 6608060	B1	20030819	US 1999-336266	19990614
	NO 9902960	A	19990817	NO 1999-2960	19990617
	HK 1023340	A1	20031224	HK 2000-102323	20000418
PRAI	US 1996-34288P	P	19961218		
	US 1997-822373	A	19970320		
	US 1997-862925	A2	19970610		
	WO 1997-US23392	W	19971217		

OS MARPAT 129:81749
AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were prepared Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z = pyridazine-3,6-diyl) which was hydrolized to the amide and the product cyclized to give title compound II.
IT **209411-00-7P 209411-01-8P 209411-02-9P**
209411-03-0P 209411-04-1P 209411-05-2P
209411-06-3P 209411-07-4P 209411-08-5P

209411-09-6P 209411-10-9P 209411-11-0P
209411-12-1P 209411-13-2P 209411-14-3P
209411-15-4P 209411-16-5P 209411-17-6P
209411-18-7P 209411-19-8P 209411-20-1P
209411-21-2P 209411-22-3P 209411-23-4P
209411-24-5P 209411-25-6P 209411-26-7P
209411-27-8P 209411-28-9P 209411-29-0P
209411-30-3P 209411-31-4P 209411-32-5P
209411-33-6P 209411-34-7P 209411-35-8P
209411-36-9P 209411-37-0P 209411-38-1P
209411-39-2P 209411-40-5P 209411-41-6P
209411-42-7P 209411-43-8P 209411-44-9P
209411-45-0P 209411-46-1P 209411-47-2P
209411-48-3P 209411-49-4P 209411-50-7P
209411-51-8P 209411-52-9P 209411-53-0P
209411-54-1P 209411-55-2P 209411-56-3P
209411-57-4P 209411-58-5P 209411-59-6P
209411-60-9P 209411-61-0P 209411-62-1P
209411-63-2P 209411-64-3P 209411-65-4P
209411-66-5P 209411-67-6P 209411-68-7P
209411-69-8P 209411-70-1P 209411-71-2P
209411-72-3P 209411-74-5P 209411-75-6P
209411-76-7P 209411-77-8P 209411-78-9P
209411-79-0P 209411-80-3P 209411-81-4P
209411-82-5P 209411-83-6P 209411-84-7P
209411-85-8P 209411-86-9P 209411-87-0P
209411-88-1P 209411-89-2P 209411-90-5P
209411-91-6P 209411-92-7P 209411-93-8P
209411-94-9P 209411-95-0P 209411-96-1P
209411-97-2P 209411-98-3P 209411-99-4P
209412-00-0P 209412-01-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors)

RN 209411-00-7 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-01-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-02-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-03-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-04-1 CAPLUS
CN 2-Pyridineacetamide, 6-(4-chlorophenyl)-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-05-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-06-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-07-4 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-4-fluorophenyl)-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-08-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-09-6 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-10-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[(hydroxyimino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-11-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 209411-12-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-13-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-14-3 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chlorophenyl)-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-15-4 CAPLUS
CN Benzoic acid, 4-[6-[2-amino-1-(2,6-dichlorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-16-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-17-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-18-7 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-19-8 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 209411-20-1 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-21-2 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-formylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-22-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-23-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-24-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-methoxyphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-25-6 CAPLUS
CN 2-Pyridineacetamide, 6-(2,4-dichlorophenyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-26-7 CAPLUS
CN 2-Pyridineacetamide, 6-(5-chloro-2-thienyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-27-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-formylphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-28-9 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-29-0 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-30-3 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-31-4 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-32-5 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-33-6 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-34-7 CAPLUS
CN Benzoic acid, 4-[6-[2-amino-1-(2-chloro-6-fluorophenyl)-2-oxoethyl]-2-
pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-35-8 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-formylphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-36-9 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-thienyl)-
(9CI) (CA INDEX NAME)



RN 209411-37-0 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-thienyl)-
(9CI) (CA INDEX NAME)



RN 209411-38-1 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-39-2 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-40-5 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-41-6 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-42-7 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(5-chloro-2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-43-8 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-44-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,5-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-45-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-46-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[[(2-hydroxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-47-2 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-48-3 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-49-4 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-50-7 CAPLUS
CN 2-Pyridineacetamide, 6-(2-benzofuranyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-51-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-52-9 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-53-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-54-1 CAPLUS
CN 2-Pyridineacetamide, α-(4-amino-2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-55-2 CAPLUS
CN 2-Pyridineacetamide, 6-benzo[b]thien-2-yl-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-56-3 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-formyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 209411-57-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[(phenylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-58-5 CAPLUS
CN 2-Pyridineacetamide, 6-[2-[[(2-aminoethyl)amino]methyl]phenyl]-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-59-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[[(2,3-dihydroxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-60-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-61-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-difluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-62-1 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-63-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-64-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-65-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-66-5 CAPLUS
CN 2-Pyridineacetamide, 6-(2,3-dichlorophenyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-67-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-68-7 CAPLUS
CN 2-Pyridineacetamide, 6-(2-chlorophenyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-69-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-70-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-71-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-72-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-74-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-75-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-76-7 CAPLUS
CN 2-Pyridineacetamide, 6-[3,5-bis(trifluoromethyl)phenyl]-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-77-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-78-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[3-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-79-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dimethylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-80-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-81-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-82-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-[(methoxymethoxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-83-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-84-7 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-85-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-86-9 CAPLUS
CN 2-Pyridineacetamide, α-(6-chloro-1,3-benzodioxol-5-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-87-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-

(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-88-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-89-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-90-5 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-(6-phenyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 209411-91-6 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-92-7 CAPLUS
CN Urea, N-(2,6-dimethylphenyl)-N-[6-(4-fluorophenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-93-8 CAPLUS
CN Urea, N-[6-(4-chlorophenyl)-2-pyridinyl]-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-94-9 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-95-0 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-2-pyridinyl]- (9CI)

(CA INDEX NAME)



RN 209411-96-1 CAPLUS
CN Urea, N-(2,6-dimethylphenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 209411-97-2 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-methylphenyl)-2-pyridinyl]- (9CI)
(CA INDEX NAME)



RN 209411-98-3 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-99-4 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209412-00-0 CAPLUS
CN Urea, N-(6-chloro-1,3-benzodioxol-5-yl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209412-01-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 18:00:29 ON 06 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 18:00:34 ON 06 JUL 2004
L1               STRUCTURE UPLOADED
L2             0 S L1 SSS SAM
L3               SCREEN 1840
L4               SCREEN 2026 OR  2039 OR  2040 OR  2045 OR  2047
L5               STRUCTURE UPLOADED
L6               QUE L5 AND L3 NOT L4
L7             1 S L6 SSS SAM
L8               SCREEN 1840
L9               SCREEN 2026 OR  2039 OR  2040 OR  2045 OR  2047
L10              STRUCTURE UPLOADED
L11              QUE L10 AND L8 NOT L9
L12            1 S L11 SSS SAM
L13              SCREEN 1840
L14              SCREEN 2026 OR  2039 OR  2040 OR  2045 OR  2047
L15              STRUCTURE UPLOADED
L16              QUE L15 AND L13 NOT L14
L17            1 S L16 SSS SAM
L18              SCREEN 1840
L19              SCREEN 2026 OR  2039 OR  2040 OR  2045 OR  2047
L20              STRUCTURE UPLOADED
L21              QUE L20 AND L18 NOT L19
L22           10 S L21 SSS SAM
L23              SCREEN 1840
L24              SCREEN 2026 OR  2039 OR  2040 OR  2045 OR  2047
L25              STRUCTURE UPLOADED
L26              QUE L25 AND L23 NOT L24
L27           10 S L26 SSS SAM
L28          162 S L26 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:14:09 ON 06 JUL 2004
L29            6 S L28

     FILE 'CAOLD' ENTERED AT 18:14:42 ON 06 JUL 2004

=> s l28
L30            0 L28

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.42     195.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -4.41

STN INTERNATIONAL LOGOFF AT 18:14:52 ON 06 JUL 2004
```